

# Apricitabine



**Drug Class:** Nucleoside Reverse Transcriptase Inhibitors

Apricitabine, also known as AVX754 or SPD754, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). NRTIs work by blocking reverse transcriptase, a protein that HIV needs to make more copies of itself.

## HIV/AIDS-Related Uses

Apricitabine is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It is being studied for the treatment of HIV infection in treatment-experienced patients and has been granted fast-track status by the FDA. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

## Dosage Form/Administration

Apricitabine is taken by mouth in clinical trials.

## Recommended Daily Dose

Daily doses of 400 to 1,600 mg have been studied in early trials. Twice-daily dosing has been selected for further study.

## Contraindications

Individuals should tell a doctor about any medical problems before taking this medicine.

## Possible Side Effects

Along with its desired effects, apricitabine may cause some unwanted effects. Further study is needed to identify these side effects.

## Drug and Food Interactions

A doctor should be notified of any other medications being taken, including prescription, nonprescription (over-the-counter), or herbal medications.

## Clinical Trials

For information on clinical trials that involve Apricitabine, visit the ClinicalTrials.gov web site at <http://www.clinicaltrials.gov>. In the Search box,

enter: Apricitabine AND HIV Infections.

## Manufacturer Information

Apricitabine  
Avexa Limited  
576 Swan Street  
Richmond Victoria, Australia  
61-3-9208-4300

## For More Information

Contact your doctor or an AIDSinfo Health Information Specialist:

- Via Phone: 1-800-448-0440 Monday - Friday, 12:00 p.m. (Noon) - 5:00 p.m. ET
- Via Live Help: [http://aidsinfo.nih.gov/live\\_help](http://aidsinfo.nih.gov/live_help) Monday - Friday, 12:00 p.m. (Noon) - 4:00 p.m. ET